Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

The Efficacy and Safety of High Dose Cholecalciferol Therapy in Hemodialysis Patients

Version 1 : Received: 6 November 2023 / Approved: 6 November 2023 / Online: 7 November 2023 (02:38:27 CET)

A peer-reviewed article of this Preprint also exists.

Tarasewicz, A.; Komorniczak, M.; Zakrzewska, A.; Biedunkiewicz, B.; Małgorzewicz, S.; Jankowska, M.; Jasiulewicz, K.; Płonka, N.; Dąbrowska, M.; Dębska-Ślizień, A.; et al. The Efficacy and Safety of High-Dose Cholecalciferol Therapy in Hemodialysis Patients. Biomedicines 2024, 12, 377, doi:10.3390/biomedicines12020377. Tarasewicz, A.; Komorniczak, M.; Zakrzewska, A.; Biedunkiewicz, B.; Małgorzewicz, S.; Jankowska, M.; Jasiulewicz, K.; Płonka, N.; Dąbrowska, M.; Dębska-Ślizień, A.; et al. The Efficacy and Safety of High-Dose Cholecalciferol Therapy in Hemodialysis Patients. Biomedicines 2024, 12, 377, doi:10.3390/biomedicines12020377.

Abstract

Vitamin D deficiency and insufficiency are highly prevalent in CKD affecting over 80% of hemodialysis (HD) patients and require therapeutic intervention. Nephrological societies suggest the administration of cholecalciferol according to the guidelines for the general population. The aim of the observational study was to evaluate the efficacy and safety of the therapy with a high dose of cholecalciferol in HD patients with 25(OH)D deficiency and insufficiency to reach the target serum 25(OH)D level > 30 ng/mL. 22 patients (16 M), with an average age of 72.5 ± 13.03 years and 25(OH)D concentration of 13.05 (9.00–17.90) ng/mL were administered cholecalciferol at a therapeutic dose of 70,000 IU/week (20,000 IU + 20,000 IU + 30,000 IU, immediately after each dialysis session). All patients achieved the target value >30 ng/mL, with a mean time of 2.86 ± 1.87 weeks. In the first week, the target level of 25(OH)D (100%) was reached by 2 patients (9.09%), in the second week – by 15 patients (68.18%), in the fourth week – by 18 patients (81.18%) and in the ninth week by all 22 patients (100%). A significant increase in 1,25(OH)2D levels was observed during the study, however, only 2 patients (9.09%) achieved a concentration of 1,25(OH)2D above 25 ng/mL – the lower limit of the reference range. The intact PTH concentrations remained unchanged during the observation period. No episodes of hypercalcemia, and one new episode of hyperphosphatemia were observed. In conclusion, our study showed that the administration of a high therapeutic dose of cholecalciferol allowed for a quick, effective, and safe leveling of 25(OH)D concentration in HD patients.

Keywords

vitamin D; cholecalciferol; 25-hydroxycholecalciferol, calcidiol; calcitriol; hemodialysis; parathyroid hormone; chronic kidney disease; chronic kidney disease–mineral; bone disorder

Subject

Medicine and Pharmacology, Urology and Nephrology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.